Upon completion of the video presentation, to finish the activity and claim your credit, please click
here.
This activity has expired, credit is no longer available.
This activity is supported by an educational grant from Lilly and Merck.
Collaborative Management of Patients with Advanced Estrogen Receptor-Positive Breast Cancer
Lee S. Schwartzberg, MD, FACP
West Cancer Center
Heather Greene, FNP, AOCNP®
West Cancer Center
The standard treatment approach for ER+ breast cancer includes surgery, radiation, or both, along with chemotherapy, endocrine therapy, targeted therapy, or combinations of these approaches. Cyclin-dependent kinase (CDK) inhibitors represent a new form of cytotoxic chemotherapy. The major side effect is hematologic toxicity, however, this differs from the hematologic effects associated with conventional cytotoxic chemotherapy. This educational program will provide advanced practitioners valuable insight into the science behind CDK inhibition, when CDKs are indicated, how to monitor for and manage side effects, as well as when and how to dose adjust.
These CME/CE/CPE accredited activities are jointly provided by
